Investigational Drug Information for Tesaglitazar
✉ Email this page to a colleague
What is the drug development status for Tesaglitazar?
Tesaglitazar is an investigational drug.
There have been 17 clinical trials for Tesaglitazar.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2005.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Insulin Resistance. The leading clinical trial sponsors are AstraZeneca and [disabled in preview].
Summary for Tesaglitazar
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 3,186 |
| WIPO Patent Applications | 1,305 |
| Japanese Patent Applications | 679 |
| Clinical Trial Progress | Phase 2 (2005-03-01) |
| Vendors | 81 |
Recent Clinical Trials for Tesaglitazar
| Title | Sponsor | Phase |
|---|---|---|
| GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes | AstraZeneca | Phase 3 |
| ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity | AstraZeneca | Phase 2 |
| GALLANT 22 Tesaglitazar vs. Placebo | AstraZeneca | Phase 3 |
Clinical Trial Summary for Tesaglitazar
Top disease conditions for Tesaglitazar
Top clinical trial sponsors for Tesaglitazar
US Patents for Tesaglitazar
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
